Vontobel Holding Ltd. grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 122.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 258,368 shares of the company's stock after acquiring an additional 142,280 shares during the period. Vontobel Holding Ltd. owned about 0.07% of Moderna worth $10,743,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Blue Trust Inc. increased its holdings in Moderna by 365.6% during the third quarter. Blue Trust Inc. now owns 731 shares of the company's stock valued at $49,000 after buying an additional 574 shares during the period. Wilmington Savings Fund Society FSB increased its holdings in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares during the period. Larson Financial Group LLC increased its holdings in Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company's stock valued at $61,000 after buying an additional 317 shares during the period. Rakuten Securities Inc. increased its holdings in Moderna by 477.3% during the third quarter. Rakuten Securities Inc. now owns 941 shares of the company's stock valued at $63,000 after buying an additional 778 shares during the period. Finally, MassMutual Private Wealth & Trust FSB increased its holdings in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after buying an additional 389 shares during the period. Institutional investors own 75.33% of the company's stock.
Insider Buying and Selling at Moderna
In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now owns 19,717 shares of the company's stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 2,664 shares of company stock worth $115,210 in the last ninety days. 15.70% of the stock is owned by insiders.
Moderna Stock Up 8.3 %
Shares of MRNA stock traded up $2.73 on Tuesday, hitting $35.72. The stock had a trading volume of 18,888,561 shares, compared to its average volume of 12,937,100. The firm has a market capitalization of $13.75 billion, a price-to-earnings ratio of -6.14 and a beta of 1.59. The stock's 50 day moving average is $38.61 and its 200-day moving average is $53.82. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the stock. Morgan Stanley cut their price objective on shares of Moderna from $70.00 to $38.00 and set an "equal weight" rating on the stock in a report on Wednesday, January 15th. Evercore ISI cut their price target on shares of Moderna from $60.00 to $50.00 and set an "in-line" rating on the stock in a report on Monday, January 27th. UBS Group cut their price target on shares of Moderna from $108.00 to $96.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Wolfe Research initiated coverage on shares of Moderna in a report on Friday, November 15th. They issued an "underperform" rating and a $40.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Moderna in a report on Friday, November 8th. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Moderna has a consensus rating of "Hold" and a consensus target price of $61.58.
Get Our Latest Report on MRNA
About Moderna
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
See Also
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
